Attached files
| file | filename |
|---|---|
| EX-31.A - EX-31.A - DUSA PHARMACEUTICALS INC | y90065exv31wa.htm |
| EX-32.B - EX-32.B - DUSA PHARMACEUTICALS INC | y90065exv32wb.htm |
| EX-99.1 - EX-99.1 - DUSA PHARMACEUTICALS INC | y90065exv99w1.htm |
| EX-31.B - EX-31.B - DUSA PHARMACEUTICALS INC | y90065exv31wb.htm |
| EX-32.A - EX-32.A - DUSA PHARMACEUTICALS INC | y90065exv32wa.htm |
| EX-21.A - EX-21.A - DUSA PHARMACEUTICALS INC | y90065exv21wa.htm |
| 10-K - FORM 10-K - DUSA PHARMACEUTICALS INC | y90065e10vk.htm |
EXHIBIT 23(a)
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration
Statement Nos.
333-150965,
333-147614,
333-134814,
333-73039,
333-84071,
333-31676,
333-33118,
and
333-113913
on
Form S-3
and Registration Statements Nos.
333-155431,
333-141615,
333-126345,
333-92259,
and
333-57890 on
Form S-8
of our report dated March 3, 2011, relating to the
consolidated financial statements of DUSA Pharmaceuticals, Inc.,
appearing in this Annual Report on
Form 10-K
of DUSA Pharmaceuticals, Inc. for the year ended
December 31, 2010.
/s/ Deloitte &
Touche LLP
Boston, Massachusetts
March 3, 2011